Duopross Meditech Corp. v. Inviro Medical Devices, Ltd. , 695 F.3d 1247 ( 2012 )


Menu:
  •   United States Court of Appeals
    for the Federal Circuit
    __________________________
    (Cancellation No. 92046702)
    DUOPROSS MEDITECH CORPORATION,
    Appellant,
    v.
    INVIRO MEDICAL DEVICES, LTD.,
    Appellee.
    __________________________
    2012-1050
    __________________________
    Appeal from the United States Patent and Trademark
    Office, Trademark Trial and Appeal Board.
    ____________________________
    Decided: August 14, 2012
    ____________________________
    THOMAS J. MOORE, Bacon & Thomas, PLLC, of Alex-
    andria, Virginia, argued for appellant. With him on the
    brief was THOMAS LEE.
    __________________________
    Before PROST, MOORE, and O’MALLEY, Circuit Judges.
    O’MALLEY, Circuit Judge.
    The Trademark Trial and Appeal Board dismissed
    DuoProSS Meditech Corporation’s counterclaims for
    cancellation of two trademark registrations owned by
    DUOPROSS MEDITECH   v. INVIRO MEDICAL                     2
    Inviro Medical Devices, Ltd., after the Board concluded
    that DuoProSS failed to prove that the marks are merely
    descriptive when used with the goods recited in Inviro’s
    registrations. Inviro Med. Devices Ltd. v. DuoProSS
    Meditech Corp., No. 92046702, Dkt. 52 (TTAB Apr. 5,
    2011) (“Board op.”). We reverse the Board’s decision
    because the Board failed to consider one of the marks as a
    whole, unduly focusing on only one portion of it; the Board
    failed to make adequate findings to support its conclusion
    that DuoProSS failed to prove descriptiveness; and the
    Board erroneously concluded that puffing could render
    the marks more than descriptive.
    I
    DuoProSS and Inviro are competitors who sell medi-
    cal syringes and needles. Their products are designed to
    prevent accidental needle sticks. Inviro’s products ac-
    complish that objective by capturing a syringe’s needle in
    the syringe barrel after use and sealing off the barrel with
    the needle inside. To accomplish that result, a person
    using an Inviro syringe (1) rotates the syringe plunger
    clockwise; (2) pulls the syringe plunger back, thereby
    drawing the needle into the syringe barrel; and (3) snaps
    off the plunger, thereby sealing the needle inside the
    barrel and making the syringe safe for handling and
    disposal. The following instructions included with In-
    viro’s products demonstrate how the products work:
    3                     DUOPROSS MEDITECH   v. INVIRO MEDICAL
    Inviro owns the two trademark registrations at issue
    in this appeal. The first, U.S. Registration No. 2,944,686,
    covers the design shown below (the “SNAP! design
    mark”):
    The SNAP! design mark is registered for use with “medi-
    cal devices, namely, medical, hypodermic, aspiration and
    injection syringes” in class 10. The second registration at
    issue is U.S. Registration No. 3,073,371, for SNAP
    SIMPLY SAFER in standard characters (the “SNAP
    SIMPLY SAFER mark”), for use with “medical devices,
    DUOPROSS MEDITECH   v. INVIRO MEDICAL                      4
    namely, cannulae; medical, hypodermic, aspiration and
    injection needles; medical, hypodermic, aspiration and
    injection syringes” in class 10.
    This case commenced when Inviro petitioned to cancel
    a trademark registration owned by DuoProSS for the
    design mark BAKSNAP, for use with a “safety syringe for
    medical use” in class 10. DuoProSS asserted counter-
    claims for cancellation of a number of Inviro’s registra-
    tions, including the SNAP! design mark and SNAP
    SIMPLY SAFER mark at issue in this appeal. Inviro
    withdrew its petition to cancel DuoProSS’s BAKSNAP
    design mark. DuoProSS, however, maintained its coun-
    terclaims against Inviro. In addition to the SNAP! design
    mark and the SNAP SIMPLY SAFER mark, Dupross
    petitioned to cancel the following of Inviro’s registrations:
    U.S. Registration No. 2,970,944, for the
    mark SNAP in typed format, for use with
    “medical devices, namely, cannulae; medi-
    cal, hypodermic, aspiration and injection
    needles” in class 10;
    U.S. Registration No. 2,778,604, for the
    mark SNAP in typed format, for use with
    “medical devices, namely, medical, hypo-
    dermic, aspiration and injection syringes”
    in class 10; and
    U.S. Registration No. 2,967,982, for the
    mark SNAP in typed format, for use with
    “medical devices, namely, medical, hypo-
    dermic, aspiration and injection syringes”
    in class 10.
    The Board sustained DuoProSS’s counterclaims as to
    the three SNAP marks in typed format. First, the Board
    noted that the ’982 registration is a duplicate of the ’604
    5                     DUOPROSS MEDITECH    v. INVIRO MEDICAL
    registration, and that Inviro agreed to voluntarily surren-
    der the ’982 registration. The Board ordered cancellation
    of the ’982 registration on that ground.
    With respect to the remaining SNAP marks in typed
    format—the ’604 and ’944 registrations—the Board con-
    sidered whether the term SNAP is merely descriptive
    when used with the goods recited in those registrations.
    The Board initially determined that the term is merely
    descriptive because it “describes a significant feature or
    function of [Inviro’s] cannulae, syringes and needles,
    namely that to safely disable them, one must snap off the
    plunger.” Board op. at 23. The Board then considered
    Inviro’s argument that the term SNAP is a double enten-
    dre and refers not only to the snapping of a syringe
    plunger, but also to the products’ ease of use: that the
    products are a “snap to use.” 
    Id. The Board found
    insuf-
    ficient evidence to demonstrate that, “upon seeing the
    mark SNAP itself, [purchasers of Inviro’s products would]
    readily understand this connotation.” 
    Id. at 26. The
    Board further found Inviro’s evidence of acquired distinct-
    iveness insufficient. 
    Id. at 26-27. For
    these reasons, the
    Board concluded that the ’604 and ’944 registrations for
    the SNAP mark in typed format were merely descriptive
    and ordered cancellation of those registrations. 1 
    Id. at 28. The
    Board, however, declined to cancel the SNAP! de-
    sign mark and the SNAP SIMPLY SAFER word mark.
    
    Id. at 28-30. While
    both of those marks contained the
    literal element SNAP, which the Board acknowledged was
    merely descriptive, the Board found that the broken
    exclamation point in the SNAP! design mark and the
    words SIMPLY SAFER in the SNAP SIMPLY SAFER
    mark rendered those marks more than descriptive. 
    Id. at 28-31. 1
      Inviro has not appealed these determinations.
    DUOPROSS MEDITECH   v. INVIRO MEDICAL                     6
    DuoProSS appeals the Board’s ruling with respect to
    the latter two marks. We address each in turn.
    II
    Substantial evidence fails to support the Board’s find-
    ing that DuoProSS failed to meet its burden to prove that
    the SNAP! design mark is merely descriptive. The evi-
    dence in the record supports no conclusion other than that
    the mark is merely descriptive.
    A mark may not be registered on the principal regis-
    ter if, “when used on or in connection with the goods of
    the applicant,” the mark is “merely descriptive . . . of
    them.” 15 U.S.C. § 1052(e)(1). A mark is merely descrip-
    tive if it “‘consists merely of words descriptive of the
    qualities, ingredients or characteristics of’ the goods or
    services related to the mark.” In re Oppedahl & Larson
    LLP, 
    373 F.3d 1171
    , 1173 (Fed. Cir. 2004) (quoting Estate
    of P.D. Beckwith, Inc. v. Comm’r of Patents, 
    252 U.S. 538
    ,
    543 (1920)). One articulation of that rule, of particular
    significance to the SNAP marks here, is that a mark is
    merely descriptive if it “conveys information regarding a
    function, or purpose, or use of the goods.” In re Abcor Dev.
    Corp., 
    588 F.2d 811
    , 813 (CCPA 1978) (citations omitted).
    The line between a mark that is merely descriptive and
    may not be registered absent secondary meaning, and one
    that is suggestive and may be registered, is that a sugges-
    tive mark “requires imagination, thought and perception
    to reach a conclusion as to the nature of the goods,” while
    a merely descriptive mark “forthwith conveys an immedi-
    ate idea of the ingredients, qualities or characteristics of
    the goods.” 
    Id. at 814 (quoting
    Abercrombie & Fitch Co. v.
    Hunting World, Inc., 
    537 F.2d 4
    , 11 (2d Cir. 1976)).
    The determination of whether a mark is merely de-
    scriptive is a question of fact. In re Dial-A-Mattress
    Operating Corp., 
    240 F.3d 1341
    , 1344 (Fed. Cir. 2001)
    7                     DUOPROSS MEDITECH   v. INVIRO MEDICAL
    (“Placement of a term on the fanciful-suggestive-
    descriptive-generic continuum is a question of fact.”) As
    the party challenging the registrations’ validity, Duo-
    ProSS bears the burden of proving that the mark is
    merely descriptive by a preponderance of the evidence.
    Cold War Museum, Inc. v. Cold War Air Museum, Inc.,
    
    586 F.3d 1352
    , 1356 (Fed. Cir. 2009). The Board con-
    cluded that DuoProSS failed to meet its burden.
    We review the Board’s factual findings supporting its
    conclusion for substantial evidence. In re Pacer Tech., 
    338 F.3d 1348
    , 1349 (Fed. Cir. 2003) (citations omitted). The
    substantial evidence standard demands deference to the
    Board. Substantial evidence is defined simply as “more
    than a mere scintilla” and “such relevant evidence as a
    reasonable mind might accept as adequate to support a
    conclusion.” 
    Id. (citation and internal
    quotation marks
    omitted). Thus, we may not reverse the Board’s decision
    for lack of substantial evidence—even if we would have
    viewed the facts differently if sitting as the tribunal of
    original jurisdiction—so long as competent evidence in the
    record supports the Board’s ruling. “Where two different
    conclusions may be warranted based on the evidence of
    record, the Board’s decision to favor one conclusion over
    the other is the type of decision that must be sustained by
    this court as supported by substantial evidence.” In re
    Bayer Aktiengesellschaft, 
    488 F.3d 960
    , 970 (Fed. Cir.
    2007).
    Even under this deferential standard of review, we
    conclude that the Board erred when it found that Duo-
    ProSS failed to prove that the SNAP! design mark is
    merely descriptive. This is so for two reasons. First, the
    Board improperly focused on only one portion of the mark
    when it considered the mark’s commercial impression.
    Second, the Board failed to make any findings to support
    its conclusion that DuoProSS failed to prove that the
    DUOPROSS MEDITECH   v. INVIRO MEDICAL                    8
    mark is merely descriptive. The findings that the Board
    did make, in fact, support the contrary conclusion.
    A
    The Board improperly separated the SNAP! design mark
    (          ) into the literal element SNAP and the bro-
    ken exclamation point. When determining whether a
    mark is merely descriptive, the Board must consider the
    commercial impression of a mark as a whole. Dial-A-
    
    Mattress, 240 F.3d at 1345-46
    . Because a mark must be
    considered as a whole, the Board may not “dissect” the
    mark into isolated elements. 
    Id. (citing Beckwith, 252
    U.S. at 545-46). See also Oppedahl & 
    Larson, 373 F.3d at 1174-75
    . That is what the Board did in this case, how-
    ever.
    The Board began by noting that the mark includes the
    “literal element SNAP,” an element that the Board had
    already determined was merely descriptive. Board op. at
    28. The Board then put the SNAP element aside and
    analyzed the exclamation point in isolation. 
    Id. at 29. The
    Board found that the exclamation point was not
    merely descriptive, characterizing it as “fanciful.” 
    Id. While the Board
    acknowledged that the exclamation point
    depicts breaking, it observed that the design “only sug-
    gests the breaking of something,” not necessarily the
    breaking of a syringe. 
    Id. The Board, in
    other words,
    believed that the exclamation point requires a consumer
    to employ “imagination, thought and perception” to de-
    termine that the function of the recited goods included the
    breaking of a syringe plunger. 
    Abcor, 588 F.2d at 814
    .
    At this point, the Board should have considered
    whether the entire mark, composed of the exclamation
    point and the descriptive word SNAP, conveys a commer-
    cial impression that is merely descriptive to a consumer.
    Dial-A-
    Mattress, 240 F.3d at 1345-46
    ; Oppedahl & Lar-
    9                     DUOPROSS MEDITECH   v. INVIRO MEDICAL
    
    son, 373 F.3d at 1174
    . The Board failed to do so. Rather,
    after considering the exclamation point in isolation, the
    Board summarily concluded that “the mark, as a whole, is
    not a merely descriptive illustration of an important
    feature or characteristic of applicant’s cannulae, syringes
    and needles.” Board op. at 29. The Board’s opinion lacks
    any indicia, however, that it actually considered the mark
    as a whole. The Board failed to explain why a mark
    composed of the admittedly descriptive word SNAP, which
    refers to a prominent function of the recited goods, and an
    exclamation point that depicts at least the breaking or
    snapping of “something” is not, when taken as a whole,
    merely descriptive of the snapping syringes.
    When DuoProSS moved for reconsideration on this is-
    sue, the Board, appearing to recognize that it had errone-
    ously dissected the mark, attempted to compensate for its
    error by noting that, “[a]lthough the word ‘SNAP’ is
    descriptive, it is physically connected to the non-
    descriptive design.” Inviro Med. Devices Ltd. v. DuoProSS
    Meditech Corp., No. 92046702, Dkt. 55 at 4 (TTAB July
    22, 2011). That additional analysis, however, was insuffi-
    cient to cure the Board’s error. In fact, it was circular,
    allowing the Board to remove the exclamation point from
    the context in which it was used so as to justify a descrip-
    tion of it as fanciful, and then use that conclusion to
    bootstrap the clearly descriptive word SNAP back into the
    mark. The Board, to be sure, may ascertain the meaning
    and weight of each of the components that makes up the
    mark. Oppedahl & Lar
    son, 373 F.3d at 1174
    . The Board,
    however, ultimately must consider the mark as a whole
    and do so in the context of the goods or services at issue.
    
    Abcor, 588 F.2d at 813-14
    . The Board failed to do so here.
    DUOPROSS MEDITECH   v. INVIRO MEDICAL                     10
    B
    In addition to dissecting the mark, the Board failed to
    cite any evidence supporting its conclusion that a mark
    incorporating the exclamation point required a consumer
    to employ “imagination, thought and perception” to de-
    termine the nature of the goods with which the mark is
    used. 
    Abcor, 588 F.2d at 814
    . The findings that the
    Board did make, in fact, contradict that view. The record,
    therefore, is insufficient to support the Board’s conclusion,
    even under the substantial evidence standard of review.
    The Board found it significant that the exclamation
    point “only suggests the breaking of something,” rather
    than a syringe plunger specifically. Board op. at 29. The
    Board, however, cited no evidence in the record support-
    ing the conclusion that a consumer would have to employ
    imagination, thought, and perception to determine that
    the mark was referring to the snapping of a syringe
    plunger. The commercial impression that a mark conveys
    must be viewed through the eyes of a consumer. Dial-A-
    
    Mattress, 240 F.3d at 1345
    (noting that competent evi-
    dence is necessary to demonstrate “the relevant purchas-
    ing public’s understanding of a contested term”). The
    Board, however, failed to cite any evidence indicating how
    a consumer would perceive a mark incorporating the
    exclamation point. In the absence of any such evidence in
    the record, the Board effectively imposed its own view
    about the commercial impression of the mark rather than
    that of the relevant consumer.
    The express findings that the Board did make, more-
    over, strongly support the conclusion that a consumer
    would perceive the SNAP! design mark as depicting the
    snapping of a syringe plunger, as opposed to merely the
    snapping of “something,” as the Board believed. As noted
    above, in determining whether a mark is merely descrip-
    11                   DUOPROSS MEDITECH   v. INVIRO MEDICAL
    tive, the Board must consider the mark in relation to the
    goods for which it is registered. “The question is not
    whether someone presented with only the mark could
    guess what the goods or services are. Rather, the ques-
    tion is whether someone who knows what the goods and
    services are will understand the mark to convey informa-
    tion about them.” In re Tower Tech. Inc., 64 U.S.P.Q.2d
    1314, 1316-17 (TTAB 2002). The Board’s own findings
    indicate that the SNAP! design mark, viewed in the
    context of Inviro’s products, does nothing other than
    depict the snapping of a syringe plunger: the prominent
    functional feature of Inviro’s goods.
    First, the Board found that Inviro’s syringes are
    packaged with instructions on how to disable the needles.
    The third step in those instructions is “Snap off plunger!”
    Board op. at 22; Inviro Med. Devices Ltd. v. DuoProSS
    Meditech Corp., Cancellation No. 92046702, Dkt. 44 at 59-
    61, Ex. C & D (“Sharp test.”). Notably, the disabling
    instructions, an image of which the Board included in its
    opinion, prominently depict the mark incorporating the
    broken exclamation point, thereby placing the mark and
    the concept of snapping the syringe plunger in the same
    context:
    DUOPROSS MEDITECH   v. INVIRO MEDICAL                     12
    Board op. at 13; Sharp test. Ex. C.
    In addition to the disabling instructions, the Board
    found that Inviro’s website “prominently pictures a bro-
    ken plunger and the word ‘Snap.’” Board op. at 22. And,
    the Board noted that Inviro’s founder, Dr. F. Ross Sharp,
    testified that “the disabling of the syringe involved a
    number of steps, one of them is breaking the plunger.”
    Board op. at 23; Sharp test. at 61. The Board further
    noted that one dictionary definition of “snap” is “[t]o break
    suddenly: break in two.” Board op. at 23 (citation and
    internal quotation marks omitted).
    The Board’s findings support no reasonable inference
    other than that a consumer viewing the SNAP! design
    mark in the context of Inviro’s products would perceive it
    13                   DUOPROSS MEDITECH   v. INVIRO MEDICAL
    as depicting the snapping of a syringe plunger. We can-
    not endorse the Board’s opinion as supported by substan-
    tial evidence when the Board failed to make any findings
    supporting its conclusion that the SNAP! design mark
    was not merely descriptive, and when findings that it did
    make support the opposite conclusion. For these reasons,
    substantial evidence fails to support the Board’s finding
    that DuoProSS failed to prove that the SNAP! design
    mark is merely descriptive.
    III
    With respect to the SNAP SIMPLY SAFER mark, the
    Board erred in finding that DuoProSS failed to prove that
    mark is merely descriptive based on a combination of
    legal and factual errors. To determine whether a compos-
    ite mark such as the SNAP SIMPLY SAFER mark is
    merely descriptive, the Board was required to examine
    the meaning of each component individually, and then
    determine whether the mark as a whole is merely descrip-
    tive. See In re St. Paul Hydraulic Hoist Co., 
    177 F.2d 214
    ,
    215 (CCPA 1949). Like its conclusion on the SNAP!
    design mark, the Board’s conclusion on the SNAP
    SIMPLY SAFER word mark is not supported by substan-
    tial evidence. The Board, moreover, legally erred when it
    concluded that puffery could render the mark more than
    descriptive.
    A
    The Board failed to cite any evidence to support its
    conclusion that DuoProSS failed to prove that the SNAP
    SIMPLY SAFER mark is merely descriptive. The Board
    acknowledged that the word SNAP is descriptive when
    used with the recited goods. Board op. at 29. Then, the
    Board analyzed SIMPLY and SAFER, and concluded that
    the combination of those words results in “a distinctive
    impression separable from the word ‘Snap . . . .’” 
    Id. The DUOPROSS MEDITECH
      v. INVIRO MEDICAL                   14
    Board, however, failed to cite any evidence from the
    record to support that view. Rather, the Board observed
    that the combination of the terms SIMPLY and SAFER
    “creates a rhyming pattern that results in a distinctive
    impression separable from the word ‘Snap,’” and “also
    forms a phrase that does not merely impart information
    about a significant characteristic of the goods.” 
    Id. The record, however,
    contains no evidence indicating that a
    consumer would focus on the alliteration formed by
    SNAP, SIMPLY, and SAFER, or that such alliteration
    would require a consumer to take the inferential step that
    the Board described. The Board’s observation about the
    alliteration constitutes its own view about the mark, not a
    finding about the commercial impression that the mark
    conveys to a consumer based on evidence in the record.
    Again, the Board’s own findings indicate, if anything,
    that SIMPLY SAFER describes the most important
    advantage of Inviro’s products: their safety. As the Board
    found, Dr. Sharp was concerned about the “terrible toll” of
    infectious diseases affecting healthcare workers from
    accidental needle sticks, prompting him to develop “a
    number of different types of safety syringes.” Board op. at
    22; Sharp test. at 12-13, 17 (emphasis added). The pur-
    pose of capturing the needle in the syringe barrel is to
    prevent a needle stick—in other words, to make the
    device safer.
    While Dr. Sharp did assert that he wanted to convey
    to consumers how easy Inviro’s products are to use, his
    testimony indicates that ease of use shaped only his
    choice of the word SNAP, not SIMPLY or SAFER. Dr.
    Sharp, for example, testified that the idea of using SNAP
    arose when a nurse told him, “‘you know, this is so easy, I
    could teach my ten-year old son to use this syringe in ten
    seconds’ and she sort of snapped her fingers like that.”
    Sharp test. at 20. He did not, however, assert that the
    15                    DUOPROSS MEDITECH   v. INVIRO MEDICAL
    idea of using SIMPLY SAFER arose from the same con-
    versation or was otherwise shaped by his desire to convey
    the products’ ease of use. 
    Id. In any event,
    even if Dr.
    Sharp’s decision to use the words SIMPLY and SAFER
    were motivated by a desire to convey the products’ ease of
    use, the Board found no evidence during its double enten-
    dre analysis that consumers would recognize such a
    meaning.
    The Board, in sum, failed to cite any evidence, and the
    record contains none, supporting its view that the allit-
    eration in SNAP SIMPLY SAFER creates a commercial
    impression that is more than merely descriptive.
    B
    The Board, moreover, erred as matter of law when it
    concluded that, because SIMPLY SAFER is a laudatory
    phrase or puffery, the phrase renders the mark more than
    descriptive. We review that legal conclusion de novo.
    Pacer 
    Tech., 338 F.3d at 1349
    .
    The Board observed that “the term ‘Simply’ modifies
    ‘Safer’ such that the phrase SIMPLY SAFER may be
    perceived a general claim of superiority regarding the
    safety of petitioner’s syringes and thus amounts to puff-
    ery.” Board op. at 29-30. The Board appeared to believe
    that this puffery removes the mark from the realm of
    descriptiveness. For that proposition, the Board cited a
    treatise section addressing “puffing” under the unfair
    competition provisions of Section 43(a) of the Lanham Act.
    
    Id. at 30 n.4
    (citing 5 J. Thomas McCarthy, McCarthy on
    Trademarks and Unfair Competition § 27:38 (4th ed.
    2009)). This case, however, concerns descriptiveness for
    purposes of trademark registerability, not unfair competi-
    tion. The same treatise on which the Board relied and
    our precedent clearly indicate that puffing, if anything, is
    more likely to render a mark merely descriptive, not less
    DUOPROSS MEDITECH   v. INVIRO MEDICAL                  16
    so. “Marks that are merely laudatory and descriptive of
    the alleged merit of a product are . . . regarded as being
    descriptive. . . . Self-laudatory or puffing marks are re-
    garded as a condensed form of describing the character or
    quality of the goods.” In re Boston Beer Co., 
    198 F.3d 1370
    , 1373 (Fed. Cir. 1999) (citing 2 J. Thomas McCarthy,
    McCarthy on Trademarks and Unfair Competition § 11:17
    (4th ed. 1996)); see also Hoover Co. v. Royal Appliance
    Mfg. Co., 
    238 F.3d 1357
    , 1360 (Fed. Cir. 2001) (citing
    Boston Beer and McCarthy for the same proposition).
    Here, adding SIMPLY SAFER to SNAP does nothing
    more than laud the safety of Inviro’s products, which, as
    discussed above, is a merely descriptive use.
    IV
    Substantial evidence fails to support the Board’s con-
    clusion that DuoProSS failed to prove that the SNAP!
    design mark and SNAP SIMPLY SAFER mark are merely
    descriptive. Accordingly, we reverse the Board’s decision
    and remand with instructions to enter judgment in favor
    of DuoProSS and to order cancellation of U.S. Registra-
    tion Nos. 2,944,686 and 3,073,371.
    REVERSED AND REMANDED